



Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

February 14, 2017

Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced today that additional secondary efficacy and safety endpoint results from the 24-week ibalizumab Phase III trial, TMB-301, were presented at a late-breaker session at the Conference on Retroviruses and Opportunistic Infections (CROI) 2017. Preliminary secondary efficacy and safety endpoint results were announced on November 10, 2016.